NCT01489423View on ClinicalTrials.gov

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

CompletedOBSERVATIONAL
Enrollment

270

Participants

Timeline

Start Date

April 26, 2013

Primary Completion Date

May 26, 2013

Study Completion Date

May 26, 2013

Conditions
Melanoma (Skin)
Interventions
GENETIC

RNA analysis

GENETIC

in situ hybridization

GENETIC

polymerase chain reaction

OTHER

enzyme-linked immunosorbent assay

OTHER

flow cytometry

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT01489423 - Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim | Biotech Hunter | Biotech Hunter